BML-190 (Indomethacin morpholinylamide) is a drug used in scientific research that acts as a selective CB2inverse agonist.[1] BML-190 is structurally derived from the NSAIDindomethacin but has a quite different biological activity.[2] The activity produced by this compound is disputed, with some sources referring to it as a CB2agonist rather than an inverse agonist;[3][4] this may reflect an error in classification, or alternatively it may produce different effects in different tissues, and more research is required to resolve this dispute.